Drugs / HUACHANSU PIAN
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03236636 Comparator | Sep 2017 → Dec 2022 | hepatocellular carcinoma | Beijing Shenogen Biomedical Co., Ltd | Unknown | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HUACHANSU PIAN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03236636 ↗ |
| Route | Oral | “Take orally” NCT03236636 ↗ |